NICE Puts Velcade Second For First-Line Multiple Myeloma; Janssen To Appeal

Janssen's Velcade and Celgene's thalidomide both recommended as first-line multiple myeloma therapies, but thalidomide is more cost-effective, says NICE's final appraisal determination.